View Older Stories View More Recent Stories

Apr 2, 2020 08:38AM Zealand Pharma completes the acquisition of Valeritas
Apr 2, 2020 05:59AM Zealand Pharma (ZEAL) Announces Business Update Related to COVID-19 Outbreak
Apr 2, 2020 05:35AM Zealand Pharma provides business update related to current COVID-19 situation
Apr 2, 2020 05:35AM Zealand Pharma provides business update related to current COVID-19 situation
Mar 31, 2020 11:36PM Correction: Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Mar 31, 2020 04:40PM Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Mar 31, 2020 12:00PM Total number of shares and voting rights in Zealand Pharma at March 31, 2020
Mar 31, 2020 09:45AM Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia
Mar 31, 2020 04:16AM Zealand Pharma completes subscription of New Ordinary Shares and registration of capital increase
Mar 30, 2020 07:34AM Zealand Pharma (ZEAL) announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery
Mar 30, 2020 07:32AM Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery
Mar 26, 2020 07:25PM Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000
Mar 26, 2020 07:25PM Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000
Mar 24, 2020 05:16PM Annual General Meeting of Zealand Pharma A/S: Measures in consequence of COVID-19
Mar 20, 2020 05:17PM Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim
Mar 20, 2020 10:26AM Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Mar 20, 2020 04:54AM Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Mar 11, 2020 05:50PM Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019
Mar 11, 2020 05:50PM Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019
Mar 9, 2020 08:26AM Update: Zealand Pharma hosts conference call on March 12 at 4 pm CET (11 am EDT) to present full year results for 2019
Mar 9, 2020 08:26AM Update: Zealand Pharma hosts conference call on March 12 at 4 pm CET (11 am EDT) to present full year results for 2019
Feb 26, 2020 03:14AM Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019
Feb 26, 2020 03:14AM Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019
Feb 20, 2020 01:30PM Zealand Pharma to attend 9th Annual SVB Leerink Global Healthcare Conference
Feb 11, 2020 07:35AM Zealand Pharma major shareholder announcement: Wellington Management Group LLP
Feb 10, 2020 05:52AM Zealand Pharma (ZEAL) Reports Bid to Acquire Valeritas for $23M
Feb 10, 2020 02:00AM Rexgenero Appoints David Horn Solomon as Chairman
Feb 9, 2020 08:40PM Zealand Pharma announces bid to acquire Valeritas
Feb 9, 2020 08:40PM Zealand Pharma announces bid to acquire Valeritas
Dec 31, 2019 12:00PM Total number of shares and voting rights in Zealand Pharma at December 31, 2019
Dec 13, 2019 09:30AM Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Dec 13, 2019 09:00AM Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Dec 11, 2019 06:30AM Zealand Pharma announces amendments to its Articles of Association following the granting of warrants
Dec 10, 2019 12:00PM Financial calendar for Zealand Pharma in 2020
Dec 10, 2019 02:00AM Zealand Pharma partner Beta Bionics receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System
Dec 5, 2019 11:16AM Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Dec 5, 2019 05:00AM Zealand Pharma grants new warrants under the employee warrant program
Dec 4, 2019 08:55AM Zealand Pharma initiates second Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
Nov 29, 2019 12:00PM Total number of shares and voting rights in Zealand Pharma at November 30, 2019
Nov 27, 2019 09:05AM Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program
Nov 22, 2019 07:00AM Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Nov 14, 2019 09:00AM Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investm
Nov 14, 2019 09:00AM Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investm
Oct 28, 2019 12:00PM Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019
Oct 22, 2019 06:14AM Zealand Pharma (ZEAL) Reports Acquisition of Encycle Therapeutics
Oct 22, 2019 06:05AM Zealand Pharma expands its peptide platform with acquisition of Encycle Therapeutics
Oct 22, 2019 06:05AM Zealand Pharma expands its peptide platform with acquisition of Encycle Therapeutics
Sep 30, 2019 11:00AM Total number of shares and voting rights in Zealand Pharma at September 30, 2019
Sep 24, 2019 06:01AM Zealand Pharma (ZEAL) Reports Positive Results in Ph. 3 Trial Sasiglucagon for Severe Hypoglycemia; Achieves Primary & All Key Secondary Endpoints
Sep 24, 2019 05:57AM Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
View More Recent Stories View Older Stories